The rise and fall of Natrecor for congestive heart failure: Implications for drug policy

被引:15
|
作者
Kesselhelm, Aaron S. [1 ]
Fischer, Michael A.
Avorn, Jerry
机构
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
D O I
10.1377/hlthaff.25.4.1095
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recent revelations of unexpected side effects of widely prescribed medications have raised questions about several aspects of U.S. drug policy, from initial Food and Drug Administration (FDA) approval to promotion by manufacturers and prescribing by physicians. One prominent example is nesiritide (Natrecor), a treatment for congestive heart failure. We use it as a case study to assess how FDA standards for drug approval, marketing practices by drug manufacturers, and physicians' prescribing choices can shape the risk-benefit relationship of new drugs. Based on the nesiritide experience, we suggest several ways to improve policies for drug approval, postmarketing surveillance, and drug utilization.
引用
收藏
页码:1095 / 1102
页数:8
相关论文
共 50 条